KIRhub 2.0· v2

Dabrafenib

38fe7287-d16c-5de7-b76e-a828b719affa · FDA Approved · targets BRAF

Dabrafenib

MeasuredReference

Dabrafenib targets RAF1, NEK9, LIMK1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RAF1 NEK9 LIMK1 LIMK2 BRAF

Top hallmarks

tumor promoting inflammation3.9k
proliferation3.6k
evading apoptosis3.5k

Top pathways disrupted

pi3k akt mtor signaling7.7k
allograft rejection7.1k
apical junction6.8k

Resistance landscape — Dabrafenib

MeasuredReference

10 known oncogenic variants exist on Dabrafenib's top targets — see detail for inhibition impact.

RAF1 1 known variant
- RAF1 (R391W)
BRAF 9 known variants

Open in new tab